Sevelamer reverses liver fibrosis by deactivation of hepatic stellate cells

• Published in: Biochemical pharmacology 2024-04, Vol.222, p.116121, Article 116121
• Main Authors: Lv, Yang-feng, Xie, Chuan-sheng, Liu, Zhi-xing, Kang, Mei-diao, Liu, Yue, Liao, Zi-qiang, Ji, Yu-long, Zhao, Rui, Li, Yan-shu, Wei, Xiao-yong, Luo, Rong-guang, Tang, Qun
• Format: Article
• Language: English
• Subjects: Animals; Antioxidants - pharmacology; Hepatic stellate cell; Hepatic Stellate Cells; Liver - metabolism; Liver Cirrhosis - chemically induced; Liver Cirrhosis - drug therapy; Liver Cirrhosis - metabolism; Liver Diseases - metabolism; Liver fibrosis; low Pi; Macrophage; Phosphorus - metabolism; Phosphorus - pharmacology; Phosphorus - therapeutic use; Rats; Sevelamer; Sevelamer - adverse effects; TGF-β; Transforming Growth Factor beta - metabolism; Transforming Growth Factor beta1 - metabolism
• ISSN: 0006-2952; 1873-2968; 1873-2968
• DOI: 10.1016/j.bcp.2024.116121

[Display omitted] Liver fibrosis is a chronic liver disease characterized by a progressive wound healing response caused by chronic liver injury. Currently, there are no approved clinical treatments for liver fibrosis. Sevelamer is used clinically to treat hyperphosphatemia and has shown potential therapeutic effects on liver diseases. However, there have been few studies evaluating the therapeutic effects of sevelamer on liver fibrosis, and the specific mechanisms are still unclear. In this study, we investigated the antifibrotic effects of sevelamer-induced low inorganic phosphate (Pi) stress in vitro and in vivo and analyzed the detailed mechanisms. We found that low Pi stress could inhibit the proliferation of activated hepatic stellate cells (HSCs) by promoting apoptosis, effectively suppressing the migration and epithelial-mesenchymal transition (EMT) of hepatic stellate cells. Additionally, low Pi stress significantly increased the antioxidant stress response. It is worth noting that low Pi stress indirectly inhibited the activation and migration of HSCs by suppressing transforming growth factor β (TGF-β) expression in macrophages. In a rat model of liver fibrosis, oral administration of sevelamer significantly decreased blood phosphorus levels, improved liver function, reduced liver inflammation, and increased the antioxidant stress response in the liver. Our study revealed that the key mechanism by which sevelamer inhibited liver fibrosis involved binding to gastrointestinal phosphate, resulting in a decrease in blood phosphorus levels, the downregulation of TGF-β expression in macrophages, and the inhibition of HSC migration and fibrosis-related protein expression. Therefore, our results suggest that sevelamer-induced low Pi stress can attenuate hepatic stellate cell activation and inhibit the progression of liver fibrosis, making it a potential option for the treatment of liver fibrosis and other refractory chronic liver diseases.